Jaw bone marrow-derived osteoclast precursors internalize more bisphosphonate than long-bone marrow precursors

Bone

Volumn 57, Issue 1, 2013, Pages 242-251

  Vermeer, Jenny A F ^a   Jansen, Ineke D C ^a   Marthi, Matangi ^a   Coxon, Fraser P ^b   McKenna, Charles E ^c   Sun, Shuting ^c   de Vries, Teun J ^a   Everts, Vincent ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bisphosphonates; Endocytosis; Jaw; Osteoclast heterogeneity; Osteonecrosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CASPASE 3; CASPASE 7; COLONY STIMULATING FACTOR 1; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PROTEIN BCL 2; PROTEIN BCL XL; RAP1 PROTEIN; RISEDRONIC ACID; TRANSCRIPTION FACTOR MAFB;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BCL 2 GENE; BCL XL GENE; CELL DIFFERENTIATION; CONTROLLED STUDY; DENDRITIC CELL SPECIFIC TRANSMEMBRANE PROTEIN GENE; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG TRANSPORT; ENDOCYTOSIS; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; INTERFERON REGULATORY FACTOR 8 GENE; INTERNALIZATION; JAW; LONG BONE; MALE; MARKER GENE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN PRENYLATION; TARTRATE RESISTANT ACID PHOSPHATASE GENE; V MAF MUSCULOAPONEUROTIC FIBROSARCOMA ONCOGENE HOMOLOG B GENE;

ALKALINE PHOSPHATASE; ALP; BISPHOSPHONATE; BISPHOSPHONATES; BP; ENDOCYTOSIS; FARNESYL PYROPHOSPHATE SYNTHASE; FPPS; INTERFERON REGULATORY FACTOR 8; IRF8; JAW; MAFB; MEDIAN FLUORESCENCE INTENSITY; MFI; ONJ; OSTEOCLAST HETEROGENEITY; OSTEONECROSIS; OSTEONECROSIS OF THE JAW; PAM; PAMIDRONATE; PBGD; PORPHOBILINOGEN DEAMINASE; RIS; RISEDRONATE; TARTRATE-RESISTANT ACID PHOSPHATASE; TRACP; V-MAF MUSCULOAPONEUROTIC FIBROSARCOMA ONCOGENE HOMOLOG B;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE MARROW CELLS; DIPHOSPHONATES; ENDOCYTOSIS; FLOW CYTOMETRY; JAW; MALE; MICE; MICROSCOPY, CONFOCAL; OSTEOCLASTS; OSTEONECROSIS;

EID: 84883621184     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.08.007     Document Type: Article

References (29)

1. Frith J.C., Monkkonen J., Auriola S., Monkkonen H., Rogers M.J. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001, 44:2201-2210.
2. Frith J.C., Monkkonen J., Blackburn G.M., Russell R.G., Rogers M.J. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997, 12:1358-1367.
3. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589.
4. van Beek E., Pieterman E., Cohen L., Lowik C., Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999, 264:108-111.
5. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
6. Monkkonen H., Auriola S., Lehenkari P., Kellinsalmi M., Hassinen I.E., Vepsalainen J., et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 2006, 147:437-445.
7. Cornish J., Bava U., Callon K.E., Bai J., Naot D., Reid I.R. Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. Bone 2011, 49:710-716.
8. Coxon F.P., Thompson K., Roelofs A.J., Ebetino F.H., Rogers M.J. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008, 42:848-860.
9. Idris A.I., Rojas J., Greig I.R., Van't Hof R.J., Ralston S.H. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 2008, 82:191-201.
10. Roelofs A.J., Coxon F.P., Ebetino F.H., Lundy M.W., Henneman Z.J., Nancollas G.H., et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010, 25:606-616.
11. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
12. Reid I.R., Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol 2012, 8:90-96.
13. Allen M.R., Burr D.B. Mandible matrix necrosis in beagle dogs after 3years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 2008, 66:987-994.
14. Arnett T. Regulation of bone cell function by acid-base balance. Proc Nutr Soc 2003, 62:511-520.
15. Helsloot R.S.J., van den Berg T., Frank M.H., Everts V. Bisphosphonate-related osteonecrosis of the jaw; a literature review and a new hypothesis. Int J Oral Res 2011, 2.
16. Everts V., de Vries T.J., Helfrich M.H. Osteoclast heterogeneity: lessons from osteopetrosis and inflammatory conditions. Biochim Biophys Acta 2009, 1792:757-765.
17. Henriksen K., Bollerslev J., Everts V., Karsdal M.A. Osteoclast activity and subtypes as a function of physiology and pathology-implications for future treatments of osteoporosis. Endocr Rev 2011, 32:31-63.
18. Kashemirov B.A., Bala J.L., Chen X., Ebetino F.H., Xia Z., Russell R.G., et al. Fluorescently labeled risedronate and related analogues: "magic linker" synthesis. Bioconjug Chem 2008, 19:2308-2310.
19. de Souza Faloni A.P., Schoenmaker T., Azari A., Katchburian E., Cerri P.S., de Vries T.J., et al. Jaw and long bone marrows have a different osteoclastogenic potential. Calcif Tissue Int 2011, 88:63-74.
20. de Vries T.J., Schoenmaker T., Beertsen W., van der Neut R., Everts V. Effect of CD44 deficiency on in vitro and in vivo osteoclast formation. J Cell Biochem 2005, 94:954-966.
21. Thompson K., Rogers M.J., Coxon F.P., Crockett J.C. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006, 69:1624-1632.
22. Yang J., Hu X., Zimmerman M., Torres C.M., Yang D., Smith S.B., et al. Cutting edge: IRF8 regulates Bax transcription in vivo in primary myeloid cells. J Immunol 2011, 187:4426-4430.
23. Everts V., Korper W., Hoeben K.A., Jansen I.D., Bromme D., Cleutjens K.B., et al. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res 2006, 21:1399-1408.
24. Jansen I.D., Mardones P., Lecanda F., de Vries T.J., Recalde S., Hoeben K.A., et al. Ae2(a, b)-deficient mice exhibit osteopetrosis of long bones but not of calvaria. FASEB J 2009, 23:3470-3481.
25. Zenger S., Ek-Rylander B., Andersson G. Long bone osteoclasts display an augmented osteoclast phenotype compared to calvarial osteoclasts. Biochem Biophys Res Commun 2010, 394:743-749.
26. Azari A., Schoenmaker T., de Souza Faloni A.P., Everts V., de Vries T.J. Jaw and long bone marrow derived osteoclasts differ in shape and their response to bone and dentin. Biochem Biophys Res Commun 2011, 409:205-210.
27. Kozloff K.M., Volakis L.I., Marini J.C., Caird M.S. Near-infrared fluorescent probe traces bisphosphonate delivery and retention in vivo. J Bone Miner Res 2010, 25:1748-1758.
28. Hokugo A., Sun S., Park S., McKenna C.E., Nishimura I. Equilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats. Bone 2013, 53:59-68.
29. Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst 2011, 103:232-240.